Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

GAITHERSBURG, Md., Aug. 30, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the U.S. Centers for Disease Control and Prevention (CDC) has provided updated guidance for those who have been vaccinated as part of a clinical trial in the U.S. The CDC guidance states that participants in the Novavax PREVENT-19 Phase 3 clinical trial meet the criteria to be considered fully vaccinated two weeks after they have completed the vaccine series.

Novavax Statement on CDC Guidance Update for COVID-19 Clinical Trial Participants

For retail traders seeking short-term profits, NVAX stock is looking interesting once again. However, it's not a good long-term investment.

Novavax Looks Like a Good Stock to Trade

RA Capital Management is a large Novavax shareholder. It owns 5.1% of NVAX stock.

Should Investors Worry a Large Novavax Shareholder Cut Position in Q2?

Bank of America

Bristol-Myers

Salesforce

Kirkland Lake Gold

It doesn't take a boatload of money to begin or further your trek to financial independence.

5 No-Brainer Stocks to Invest $400 in Right Now

The upside potential appears to be much greater for this vaccine stock.

3 Reasons Why Novavax Stock Will Likely Beat Moderna Over the Next Year

Axsome Therapeutics

AstraZeneca

Nasdaq

Pieris Pharma

Roche Holding AG

Cassava Sciences Inc

Seagen

Sanofi

Over the last few years, three tiny biotechs emerged out of nowhere to give amazing returns to early investors. Which biotech might pull off a similar feat in 2022?

Which Biotech Stock Will Shock the Market in 2022?

Coinbase

Snowflake

These are some of the quickest-growing large-cap companies over the next four years.

4 Large-Cap Stocks Expected to Increase Sales 508% to 1,118% by 2024

The price of NVAX stock reflects hope in the company's Covid-19 vaccine, but hope doesn't change their poor fundamentals. The post Novavax Is Selling a Dream, But You Should Live in Reality appeared first on InvestorPlace.

Novavax Is Selling a Dream, But You Should Live in Reality

Despite the delays in FDA approval, Novavax has made strong strides in the industry, making NVAX stock is a great pharma stock to buy. The post The Pandemic Is Not Over, And Novavax Is a Strong Contender  appeared first on InvestorPlace.

The Pandemic Is Not Over, And Novavax Is a Strong Contender

Maybe not here, but elsewhere and in investors accounts NVAX stock is readying to help in big ways in the coming weeks and months. The post Put Novavax Stock on Your Radar for Buying appeared first on InvestorPlace.

Put Novavax Stock on Your Radar for Buying

Agios Pharmaceuticals

Exelixis

Johnson & Johnson

Moderna

SAGE Therapeutics

Vertex Pharmaceuticals

Biotech stocks are worth considering. Risk aside, big pharma firms can still produce big pharma returns at the end of the day.

7 Best Biotech Stocks to Buy in 2021 with Huge Upside

The potential for a third shot is giving them a boost.

Why Shares of Moderna and Novavax Are Higher This Morning

GAITHERSBURG, Md., Aug. 25, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Novavax' recombinant nanoparticle protein vaccine candidate is being studied in OCTAVE-DUO, now underway in the UK to evaluate the safety and immunogenicity of a third COVID-19 vaccine dose in participants with impaired immune systems.

Novavax to Participate in OCTAVE-DUO Study to Evaluate Third Dose of Vaccine in Participants with Impaired Immune Systems

BioNTech SE

Pfizer

The euphoria over full FDA approval of the Pfizer-BioNTech vaccine appears to be waning.

Why Pfizer, BioNTech, Moderna, and Novavax Stocks Are Sinking Today

Novavax stock has declined by almost 10% over the last week (five trading days), compared to the S&P 500 which has remained roughly flat over the same period. There have been multiple developments that appear to have impacted the stock.

Will Novavax Stock Bounce Back After Falling 10% Last Week?

NextEra Energy

Palo Alto Networks

Walgreens

If your investing horizon is measured in years, these stocks can be surefire moneymakers.

5 No-Brainer Stocks to Invest $1,000 in Right Now

Hint: Pfizer, BioNTech, and Moderna didn't make the list.

3 Top COVID Vaccine Stocks That Wall Street Is Bullish About

Both of these companies are packed with opportunities.

2 Biopharma Growth Stocks to Buy and Hold for Years

The U.S. is ramping up its ability to produce more COVID-19 vaccines.

Why Moderna, BioNTech, and Novavax Stocks Climbed Today

Its vaccine candidate may not have been first in the running. But now with even more ways for NVAX stock to soar from here, now may be the time to buy.

Novavax Stock Could Remain a Winner, Despite its ‘Also Ran' Status

Dynavax Technologies

Inovio Pharmaceuticals

Investors appeared to be rattled by the U.S. government's decision to move forward with booster doses of mRNA vaccines.

Why Dynavax, Novavax, and Inovio Stocks Sank This Week

A couple of developments likely factored into the declines for these vaccine stocks.

Why Moderna, BioNTech, and Novavax Stocks Sank Today

By helping to address the international lack of Covid-19 vaccine access, NVAX stock may be a player in the Covid-19 vaccine race after all.   The post Novavax Is Not a Sure Thing, But It's Getting Closer appeared first on InvestorPlace.

Novavax Is Not a Sure Thing, But It's Getting Closer

Blink Charging

Riot Blockchain

Revenue for these fast-paced stocks should skyrocket between 1,100% and 4,200% by mid-decade.

4 Hypergrowth Stocks Expected to Increase Sales 1,100% (or More) by 2025

Planet Fitness

Our Fool roundtable picks three COVID stocks they think are dangerous at these prices.

News for Novavax Stock (NVAX)